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Abstract 
 
Aggresomes are  protein aggregates found in mammalian cells when  the  intracellular protein 
degradation  machinery  is  over-titred.  Despite  they   abound  in  cells  producing  
recombinant proteins of biomedical and  biotechnological interest, the  physiological roles of 
these protein clusters and  the functional status of the embedded proteins remain basically 
unexplored. In this work, we have  determined for the  first time that,  like in bacterial inclusion 
bodies, deposition of recombinant  proteins  into  aggresomes does  not  imply  functional  
inactivation.  As  a  model , 
human -galactosidase A (GLA) has been expressed in  mammalian  cells  as enzymatically 
active, mechanically stable aggresomes showing higher thermal stability than  the  soluble GLA 
version. Since  aggresomes are  easily  produced and  purified,  we  propose these particles  as 
novel functional biomaterials with potential as carrier-free, self-immobilized catalyzers in 
biotechnology and  biomedicine. 
 
 
 
 
 
 
 
Keywords:  recombinant protein, protein nanoparticles, immobilized catalyzer, aggresomes.
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Introduction 
 
 
Contrarily to what  had  been previously stated, inclusion bodies (IBs) produced by recombinant 
bacteria  are   formed  by  biologically  active  polypeptides  embedded  in  amyloid-like  
networks (Garcia-Fruitos et  al. 2005;  Tokatlidis et  al. 1991;  Worrall and  Goss, 1989) . The  
unexpected application  of IBs  as versatile,  functional  and  biocompatible  materials  paves the  
road  for their use as self-immobilized  catalysts  when  formed  by enzymes like  reductases 
(Garcia-Fruitos  et al. 2005),  oxidases (Nahalka and  Nidetzky, 2007;  Nahalka et al. 2008a), 
kinases (Nahalka et al. 
2006;  Nahalka and  Patoprsty, 2009),  phosphorylases  (Nahalka, 2008)  and  aldolases  (Nahalka 
et  al.  2008b),  or  as therapeutic  agents in  protein  replacement  therapies  when   formed  by 
therapeutic proteins (Cano-Garrido et al. 2013;  Seras-Franzoso et al. 2013a; Seras-Franzoso et 
al.  2013b;   Seras-Franzoso  et  al.  2014;   Vazquez  et  al.  2012).   Mammalian  cells  instead  of 
bacteria  are  preferred  factories for  eukaryotic  protein  production,  because of  their ability  
to perform   proper    post-translational  modifications.   In   the   late   90´s,   Johnston  showed  
the accumulation of recombinant proteins in subcellular structures of mammalian cells, named 
“aggresomes” (Johnston et  al. 1998).  Aggresome formation has been attributed to  a  cellular 
response to misfolded, non-proteolyzed proteins that deposit around the microtubule-organizing 
center (MTOC) by active transport on microtubules. Their formation is prevented by disruption of 
the  dynein-dynactin  complex,  suggesting  that  dynein  protein  is  the  motor  of  this  transport 
(Garcia-Mata et  al. 1999).  Aggresomes show a surrounding cage of intermediate filament (IF) 
proteins, like vimentin (Johnston et  al. 1998),  and  contain proteasome subunits, ubiquitin and 
chaperones, consistent with their formation in response to cellular stress. Apart from the  main 
aggregated protein  species, aggresomes also  contain  Hsc70,  Hsp40  proteins  Hdj1  and  Hdj2, 
and  the  chaperonin  TriC/TCP  (Garcia-Mata et  al.  1999;  Johnston et  al.  1998;  Wigley  et  al. 
1999).   However,  the  most  consistent components of  aggresomes are  intermediate  filament 
proteins.  Even   though   many   efforts  have   been  devoted to  reveal  formation  mechanisms, 
composition  and  biological  roles  of aggresomes  (Garcia-Mata et  al.  1999;  Garcia-Mata et  al. 
2002;  Johnston et  al.  1998;  Johnston et  al.  2000;  Junn  et  al.  2002;  Kopito,  2000;  Kopito  and 
Sitia, 2000;  Wigley et  al. 1999),  putative functionality and  biological activities of the  proteins 
embedded within them have  been so far basically unexplored. 
 
 
In the present study  we demonstrate, for the first time, that mammalian cell aggresomes, like in 
the  case of bacterial IBs, retain the  biological activity of the  forming recombinant protein. By 
taking  the  human -galactosidase A (GLA) as a  model,  we  have   obtained  fully  active  and 
functionally  and   mechanically  stable  aggresomes that  perform  very  efficiently  in  enzymatic 
processes. These results  are  discussed  in  the  context  of emerging  nanostructured materials 
that when  being functional and  biocompatible, might have  intriguing applications in biomedicine, 
in order  to package functional proteins that,  because of their post-translational modifications, 
cannot be produced in bacteria as functional IBs.
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Material and Methods 
 
 
Production of recombinant GLA 
 
 
The  expression vector  pOpinE-GLA encodes a  full-length  version   of  the  human GLA gene, 
cloned   into  pOPINE  plasmid  (Berrow   et  al.  2007).   The  suspension-adapted  HEK  (human 
embryonic  kidney)  cell  line  FreeStyle™  293-F  (Invitrogen™,  Life  Technologies,  ref.  R790-07) 
was used  to  produce  GLA by  polyethylenimine  (PEI)-mediated  transient gene  expression. 
Details  of  GLA production  and  purification  have   been previously  described  (Corchero et  al. 
2011). 
 
 
Detection of recombinant GLA in transfected cells 
 
 
To estimate GLA accumulation into different cellular fractions, 1-mL samples of transfected cells 
were   harvested (3,  4  and  5  days after  transfection),  centrifuged  (15  min,  15000   rpm)  and 
supernatants separated from cells. Cell pellets were  resuspended in 1 ml of 0.01  M acetic acid 
pH  4.5  and   disrupted  by  sonication. After  centrifugation  (15  min,  15000   rpm),  supernatant 
containing  soluble  intracellular  fraction  was  separated,  and   pellet  containing  intracellular 
insoluble  fraction  was resuspended  in  1  ml  of  0.01  M acetic  acid  pH  4.5.   All these three 
Ssamples were  then  analyzed by SDS-PAGE and  western-blot developed with a rabbit anti-GLA 
serum (a-gal A H-104:  sc-25823, Santa Cruz  Biotechnology).  Amounts of GLA  in each fraction 
were  estimated  by comparison, after SDS-PAGE and western-blot,  with  known  amounts of a 
recombinant soluble GLA  produced in our laboratory. Samples and  GLA standards were  ran  in 
the  same gel  and  processed as a  set. Densitometric  analyses  were  performed  with  Quantity 
One  software  (Bio-Rad  Laboratories,  Inc).  Recombinant  GLA present in  the  three   
fractions (extracellular, intracellular soluble and  intracellular insoluble) were  used to estimate 
the  “Total” recombinant GLA produced (taken  as 100%  of recombinant protein produced), and  
then  the values from each fraction were  compared to this “Total” value to obtain the 
percentages shown 
in Table 1. 
 
 
Aggresome formation was also checked by transmission electronic microscopy (TEM). For that, 
a total  of 107   cells  were  taken   before transfection (as negative control) and  at different times 
post-transfection. After centrifugation (5 min, 1200  rpm), cell pellets were  resuspended in 2.5 ml 
of fixing solution (paraformaldehyde 2%,  glutaraldehyde 2.5%).  After fixation (15  min, at room 
temperature), samples  were  stored at  4ºC  until  TEM analysis.  Samples  were  observed in  a 
JEM-1400 transmission electron microscope (Jeol) with a CCD GATAN ES1000W Erlangshen 
camera. 
 
 
Aggresome purification
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At 5  days post-transfection,  the  soluble,  secreted GLA present in  the  culture  medium  was 
separated from cells by centrifugation (15 min, 15000  rpm) of transfected cultures. Supernatants 
were  removed and  cell pellets were  used to purify aggresomes. The  protocol and  “disrupting 
buffers”  previously  described  (Garcia-Mata et  al.  1999)  were  used for cell  lysis.  Briefly,  cell 
pellets were  resuspended with either 2% Triton X-100 in PBS,  IPB buffer (10 mM Tris-HCl, pH 
7.5,  5 mM EDTA, 1% NP-40,  0.5%  deoxycholate, 150  mM NaCl), or RIPA buffer (50 mM Tris- 
HCl, pH 8, 1% NP-40,  0.5% deoxycholate, 0.1% SDS,  150 mM NaCl). Since GLA is a lysosomal 
enzyme (with  optimal  activity  at  pH  4.5),  it  is  likely  that  incubation  in  an  acidic  buffer  would 
better  preserve its  enzymatic  activity  than  IPB  or RIPA buffers  (with  higher pH, deleterious  for 
GLA enzymatic activity). Therefore, a  fourth “disrupting buffer” was included: IPB buffer was 
modified by replacing 10 mM Tris-HCl with 0.01  M acetic acid  at pH 4.5. Thus,  the final “acetic 
acid  disrupting buffer” composition was 0.01  M acetic acid at pH 4.5, supplemented with 5 mM 
EDTA,  1%   NP-40,   0.5%   deoxycholate,  and   150   mM  NaCl.  All   disrupting  buffers  were 
supplemented with a protease inhibitor cocktail (Complete EDTA-free, Roche). Cells were 
resuspended in the corresponding buffer, incubated for 30 min on ice, and  then  passed 10 times 
through   a  25-gauge needle.  Soluble  and  insoluble  intracellular  fractions  were  separated 
by centrifugation (6,000  rpm,  2 min, 4ºC).  Supernatants were  eliminated, and  pellets 
containing aggresomes were  washed with acetic acid  0.01  M, pH 4.5. After wash,  GLA 
aggresomes were centrifuged (6,000  rpm,  2 min, 4ºC),  resuspended again in acetic acid  
buffer (usually 20-fold concentrated respect to initial cell culture volume), aliquoted and  stored at 
-80ºC until tested. 
 
 
To  compare amounts  of  aggresomes  recovered by  using  different  disrupting  buffers,  equal 
volumes  of purified  aggresomes were  analyzed  by SDS-PAGE and  further  Coomasie staining 
and western-blot. 
 
 
Characterization of recombinant GLA aggresomes 
 
 
Enzymatic activity of soluble GLA and  aggresomes was assayed,  in vitro, fluorometrically as 
described by Desnick (Desnick et al. 1973)  and  Mayes (Mayes et al. 1981).  Briefly, activity was 
assayed using  as substrate 4-methylumbelliferyl-α-D-galactoside  (4MUG, Sigma  Chemical),  at 
2.46  mM in assay buffer (0.01  M acetic acid,  pH  4.5).  Reaction mixtures contained 100  µl 
substrate and  25 µl enzyme sample, in which purified aggresomes were  diluted in acetic acid in 
order to assure readings falling  within  the  standard  curve   range. Reactions  took  place  in 
agitation (37ºC,  1 hour),  and  were  stopped with 1.25  mL of 0.2 M glycine-NaOH (pH 10.4).   
The released product (4-methylumbelliferone, 4-MU) was determined by fluorescence measurement 
at  365  and  450  nm as excitation  and  emission  wavelengths,  respectively.  Samples  of 
commercial product 4-MU (Sigma Chemical) ranging from 5 to 500 ng/mL in 0.2 M glycine- NaOH 
buffer, pH 10.4, were used to obtain a calibration curve in order to transform fluorescence readings into 
product 4-MU concentration.  Specific enzymatic activities are  expressed as µmol 
4-MU/h/mg protein.
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To  identify  the  main  proteins  detected by  Coomasie  staining  in  purified  aggresomes,  
their corresponding bands were  cut  out  from the  stained gels and  trypsin  digested. The  
resulting peptides were  analyzed (by “peptide mass fingerprint”) by matrix-assisted laser 
desorption/ionization  (time-of-flight),  MALDI-TOF, and  their  sequences compared to SwissProt 
2011_03 database. 
 
 
Size distribution of aggresomes was measured by dynamic light scattering (DLS) at  633  nm 
wavelength,  combined  with  non-invasive  backscatter technology  (NIBS)  in  a  DLS  analyzer 
(Zetasizer Nano ZS, Malvern Instruments Limited, Malvern, U.K.). Dispersions of purified 
aggresomes were  prepared by sonication (2 min, 0.5 seconds on/off cycles, room temperature), 
diluted in acetic acid buffer, and measured at 20ºC without filtering. Mean value of three 
measurements was taken   as the  hydrodynamic  aggresome diameter.  The software used to 
analyze the data is derived from a deconvolution of the measured intensity autocorrelation function 
of the sample, using  a non-negatively constrained least squares (NNLS) fitting algorithm 
(software provided by Malvern with the Zetasizer instrument). The “Mean intensity” of the peak 
obtained (instead of the z-average number) was used as an estimation of the aggresomes 
diameter (in nm), since  the  z-average mean size  can  be sensitive to the presence 
of even  small populations of big aggregates. 
 
 
Purified  aggresomes were  also  checked by  scanning  electronic  microscopy  (SEM) . For  that, 
they were  deposited on Nuclepore Track-Etched polycarbonate membranes with pore  size  of 
0.2 µm (Whatman Ltd., United Kingdom). Then,  samples were  fixed with 2.5% glutaraldehyde in 
 
0.1 M phosphate buffer (PB, pH 7.4),  washed 4 times (10 min each) in 0.1 M PB, post-fixed in 
 
1% (wt/vol) osmium tetraoxide with 0.7% ferrocyanide in PB, washed in water,  dehydrated in an 
ascending  ethanol  series  (50,  70,  80,  90,  and  95%  for  10  min  each and  twice  with  
100% ethanol), and  dried by critical point drying with CO2. Samples were  mounted on adhesive 
carbon films  and   coated  with  gold.  Images  were   taken   with  an  EVO®  MA 10  scanning  
electron microscope (Zeiss) at an accelerating voltage of 20 kV and  an EDS Oxford INCA 
detector. 
 
 
Spontaneous release of GLA from aggresomes 
 
 
The  putative spontaneous release of GLA enzyme from aggresomes when  incubated at  37ºC 
(that   could  interfere  in  reusability  experiments)  was  checked.  For  that,   aggresomes  
were incubated at 37ºC  in agitation. At different time-points, samples were  taken  and  
centrifuged (15 min, 15000  rpm) in order  to separate aggresomes from solubilized GLA that  
could have  been released to the  supernatant. After centrifugation, supernatants were  
separated and  remaining aggresomes resuspended in  their  original  volume  with  0.01  M 
acetic  acid,  pH  4.5.  Finally, enzymatic activity and western-blot of aggresomes and 
supernatants were  performed.
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Thermal stability of soluble GLA and  aggresomes 
 
 
Soluble  GLA and   aggresomes  were   diluted  in  0.01   M  acetic  acid,   pH  4.5,  aliquoted  and 
incubated  at 37ºC. At different time periods,  samples were taken  and  directly submitted to the 
enzymatic activity test.  In the  aggresome samples, putative solubilized/released enzyme and 
enzyme still in the aggregated state were  not separated, meaning that measured activities were 
the  summary of those from both  released and  aggregated enzyme. Activity of the  aliquots was 
compared to that determined for aliquots kept always at -80ºC,  used as a reference. 
 
 
Reusability of GLA aggresomes 
 
 
Before testing aggresomes reusability, they  were  incubated for 1 h at 37ºC,  in agitation. Then, 
aggresomes were  centrifuged  (15 min,  15000  rpm) to discard  GLA spontaneously released  to 
the supernatant. Aggresomes were  resuspended in their original volume with 0.01 M acetic acid, 
pH 4.5. After that, reusability was evaluated by performing successive enzymatic activity 
measurements as described before. After each reaction cycle,  aggresomes were  recovered by 
centrifugation  (15   min,  15000   rpm).   Supernatants  containing  the   reaction  product   were 
transferred to  a  tube  with 1.25  ml of 0.2  M glycine-NaOH buffer (pH  10.4).  The  amount of 
product  released was determined as mentioned before. Aggresomes were  washed with assay 
buffer and  resuspended again in 25 µl. Then,  fresh substrate was added and  next measurement 
was carried out and  compared with the first round (defined as 100%).
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Results 
 
 
GLA expression and  formation of aggresomes 
 
 
Expression  and   accumulation  of   GLA  into   the   extracellular,  and   soluble  and   
insoluble intracellular fractions were  checked by  SDS-PAGE and  western-blot, showing a  
progressive accumulation  of  GLA  into  these  three   cellular  fractions  (Figure   1).  At  day   5,  
the   total, accumulated GLA reached >160  µg/ml. From  that,  50% corresponded to  the  
soluble from, secreted form of the enzyme, while the rest  remained intracellular, either as 
soluble (10.6%)  or insoluble versions (40%)  (Table 1).  Intracellular protein shows an  
apparent molecular weight slightly  lower  than   that   of  the   secreted  form  (Figure   1).  
Trypsin   digestion  of  the   band corresponding  to GLA embedded into  aggresomes and  
peptide  mass fingerprint  identified  12 
sequences  matching   GLA  theoretical   sequence.  From   such  12   sequences,  two  of  them 
 
(MQLRNPELHLGCALALR and  NPELHLGCALALR) were  located within the GLA signal peptide 
 
(residues 1-17 and 5-17, respectively). 
 
 
GLA expression and  accumulation  into  aggresomes were  visualized  by  TEM (Figure  2).  In 
contrast to images from cells before transfection (Figure  2, a and  b), images taken  at 3 
and   5  days  post-transfection  (Figure   2,  c  to  f)  revealed  clearly  visible  aggregates 
throughout the  cytoplasm,  not  present before  transfection.  Since all samples used to 
obtain TEM images (including cells before transfection) were treated simultaneously, with the 
same protocol and  reagents, and  moreover cytoplasmic protein aggregates are  only 
seen after transfection (and therefore, after GLA expression) , the  structures identified as 
aggresomes are not expected to be an experimental artifact. Such  aggregates are  not 
homogeneous, but  formed  by  the  self-assembly  of  smaller,  repeated building  blocks, 
consisting on spherical structures of 50-100 nm in diameter. 
Purification of aggresomes 
The amount and  purity of recovered aggresomes was determined by SDS-PAGE and  western- 
blot. According to  densitometric  analysis  of  membranes, samples obtained with  RIPA 
buffer contained the  lowest GLA amounts, while the  use of “acetic acid  disrupting buffer” 
allowed to recover 1.3-,  1.5- and  2-fold more  recombinant protein within aggresomes than  that  
found with Triton, IPB and  RIPA buffers, respectively. Presence of solubilizing agents, like SDS  
in RIPA buffer, could explain this fact, since  some of the  protein initially entrapped within 
aggresomes could  be  solubilized  (and   therefore  lost  from  the  insoluble  fraction)  during  the  
purification process. Irrespective  of the  buffer used, protein  patterns within  such  structures are  
essentially the same (not shown),  suggesting that disruption buffer does not significantly affect 
aggresome purity and  composition.
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Enzymatic and architectonic characterization of aggresomes 
 
 
Since large protein aggregates are typically monitored at 350-360 nm, and in order to avoid any 
interference  in  the  enzymatic  assay readings  due  to  the  presence of  such   aggregates, an 
absorbance spectra control (in the range of 300  to 450 nm) of 100-fold diluted aggresomes was 
performed, resulting in absorbance values <0.1. Therefore, no interference from aggresomes is 
expected when performing the GLA enzymatic assay. Performing the GLA enzymatic assay using 
GLA aggresomes as sample showed that  aggregation  and  incorporation  of  GLA into 
aggresomes did not result into enzymatic inactivation, as shown in Table 2. Aggresomes purified 
in  “acetic  acid  disrupting  buffer”  clearly  showed  the  highest  specific  activity,  which  is  not 
surprising since  pH of this buffer is optimal for GLA activity.  The  specific activities for the  more 
active aggresomes and  for soluble GLA (Corchero et al.   2011)  were  1,09533 and 1,947259 
 
µmol/h/mg  protein,  respectively.  That  means that  GLA incorporated  into  aggresomes retains 
 
56%  of the  specific  activity  of its  soluble counterpart. Taking  into  consideration these results, 
we chose the “acetic acid disrupting buffer” to purify functional aggresomes used next. 
 
 
Size of aggresomes was determined by  DLS.  When  cheking  the  distribution of sizes of our 
samples, results showed in all samples the presence of one main peak (corresponding to more  than 90-
95% of the sample intensity), and then in some cases, the presence of some impurities of higher sizes, but 
corresponding to very small populations (less than 5-10%) in the sample (data  not  shown).  
Regarding the  number of decays in the  auto-correlation functions, our  data performedalways 
giving a unique, single exponential decay function, indicative of the presence of a main population. After 
this single decay, signal showed in some cases some scattering very near to the X axis, probably indicative 
of (and supporting) the presence of the above mentioned impurities  in  the  form  of “big”  aggregates.  
The polydispersity indexes obtained were 0.446  +/- 
0.023,  0.616  +/- 0.018,  0.685  +/- 0.043,  and  0.328  +/- 0.029  for Triton,  IPB,  RIPA and  “acetic 
acid” disrupting buffers respectively, indicative that samples  are  suitable  for the  dynamic  light 
scattering (DLS) analysis. 
Aggresomes  purified  by using  the  disrupting  buffers  previously  described  (Garcia-Mata et  al. 
 
1999)  showed sizes around 1 µm of diameter: 792 +/- 111,  1037 +/- 38 and  915 +/- 97 nm for 
Triton,  IPB  and   RIPA buffers,  respectively  (Table  2),  in  agreement  with  TEM  
observations (Figure   2e  and   2f).  Interestingly,  DLS  determination  of  aggresomes purified  
in  “acetic  acid disrupting buffer” resulted in higher values (1698 +/- 29 nm in diameter), in 
agreement with SEM images (Figure  3). 
 
 
The  spherical building blocks detected in TEM images were  also clearly visible by SEM  (see 
Figure  3b),  confirming the  “aggregate of aggregates” architecture of aggresomes.  Structures 
seeing in both TEM (within transfected cells) and SEM (protein aggregates already purified) show the 
same architecture: they seem to be formed by the coalescence of small aggregates
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(of about 50 nm), which is distinctive of aggresomes. However, the building blocks seen in SEM 
 
are  not as tightly packed that those seen in TEM (compare Figure  2f with Figure  3b). 
Compositional analysis of aggresomes 
Analysis of purified aggresomes by SDS-PAGE and further Coomasie staining showed that such 
protein aggregates are  not completely pure.  On the  contrary,  some other  cell proteins co- 
aggregate   with   recombinant   GLA   during   aggresomes   formation,   appearing   later   as 
contaminants in purified aggresomes. This allowed us to determine the nature of some of such 
contaminant proteins by cutting off from the stained gel the bands corresponding to these main 
contaminants. MALDI-TOF analysis was performed on the four predominant proteins (according 
to Coomasie staining) found in purified aggresomes. Results confirmed that one  of these bands 
corresponded  to   human  GLA  enzyme  or   its   precursor.  Finding   GLA  precursor  within 
aggresomes was not  surprising, since  some unprocessed GLA molecules still containing the 
secretion   peptide   might   be   trapped  within   aggresomes.   Chaperone  Hsp70    was  found 
associated to aggresomes in significant amounts. Also, tubulin (a protein marker  for MTOC) and 
actin (the  monomeric subunit of the  cytoskeleton microfilaments) are  important components of 
aggresomes. 
 
 
Spontaneous solubilization of aggresomes 
 
 
During  the  first  hour  of  incubation  at  37ºC,   ~20-25%  of  the  GLA initially  entrapped within 
aggresomes was released to the supernatant, indicative of a spontaneous protein solubilization 
and   release.  Afterwards,  the   aggresomal  fraction  remained  basically  constant.  This  was 
confirmed by both the decrease of enzymatic activity in the insoluble fraction (Fig. 4a) in parallel 
with  the  appearance of activity  in  the  supernatant (corresponding  to solubilized  enzyme) (Fig. 
4b). Enzyme solubilization during the first hour was also confirmed by western-blot (Fig. 4c and 
 
4d). 
 
 
Stability and reusability of aggresomes 
 
 
Thermal stabilities of soluble GLA and  aggresomes were  compared by following their enzymatic 
activity  after incubation in  acetic  acid  buffer,  at 37 ºC. A clearly  higher stability  of aggresomes 
was observed (Fig. 5a),  as the  activity of soluble GLA decreased rapidly, with less than  5 % of 
activity  remaining  after  1 day.  However, for aggresomes, 68  % and  79  % of activity  remained 
after  7  and   14  days,   respectively.  These  results  indicate   that GLA embedded within the 
aggresomes  is   “protected”   and   more   resistant  to   thermal   inactivation   than   its   soluble 
counterpart. According to our results, soluble GLA is very sensitive to heat-inactivation. 
Therefore, putative released GLA from aggresomes, even if not separated from aggresomes
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before testing, is not expected to interfere significantly in the final enzymatic activity found for 
 
aggresomes, especially after several days at 37ºC. 
 
 
Regarding reusability (determined by successive enzymatic assays after aggresomes recovery 
from the reaction mixture by centrifugation), aggresomes are  easily recovered and,  according to 
the  results, could be  reused at  least in 5 consecutive enzymatic assays. A 70%  of enzymatic 
activity still remained after 5 rounds (Fig. 5b).  Since aggresomes had been incubated 1 hour at 
37ºC and the spontaneously GLA released eliminated by centrifugation before starting the 
reusabilityexperiments, this drop in the enzymatic activity along consecutive assays is probably 
due to loss of aggresomes during centrifugation steps.
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Discussion 
 
 
Through    the   production   of   a   model   GLA  in   recombinant   mammalian   cells,   we   have 
demonstrated, for the  first  time,  that  mammalian  cell  aggressomes retain  at  significant  extent 
the biological activity of the forming protein, similarly to what had  been observed in bacterial IB 
(Garcia-Fruitos et  al. 2005;  Garcia-Fruitos et  al. 2007).  Contrarily to the  conventional view on 
these protein particles, this observation indicates that  these protein clusters are  not 
exclusively composed by misfolded proteins but probably by functional folding intermediates or 
by a mixture of  misfolded  and  properly  folded  proteins.  Since  GLA incorporated  into  
aggresomes  shows 
56% of  the  specific activity  of  its soluble counterpart, the  possibility of residual activity  by 
cross-contamination with soluble enzyme during purification should be  discarded. Interestingly, 
although it has been never  quantitatively determined, GFP aggresomes are  fluorescent (Garcia- 
Mata  et  al. 1999;  Garcia-Mata et  al. 2002;  Shimohata et  al. 2002),  indicating that  the  GLA 
activity determined in the present study is not a peculiar case. 
 
 
According to solubilization experiments, around 20-25  % of the  GLA initially entrapped within 
aggresomes is solubilized and  released to the  supernatant under  mild conditions (as shown in 
Fig. 4). The  protein solubilized from aggresomes at early incubation times shows poor  thermal 
stability, and  become heat-inactivated (Fig. 4b) soon after its release from the  aggresome. 
The enzyme still remaining within aggresomes after 1 hour of incubation seems to form a core  
highly resistant  to  solubilization.  This  “bimodal”  architecture  of  aggresomes  might  be  
functionally similar to  that  proposed for bacterial IBs, in which a  fraction of functional 
releasable protein coexists with mechanically stable, non-functional versions of the same 
protein  (Cano-Garrido et al.  2013).  Probably  related  to such conformational  heterogeneity,  
GLA aggregates are  formed 
by the  assembly of smaller, repeated building blocks consisting on spherical structures of 50- 
 
100  nm in diameter (Fig. 3). This aggresome architecture, called “aggregate of aggregates”, is 
in agreement with previous reports (Garcia-Mata et al. 1999;  Ioannou et al. 1992;  Kopito, 2000; 
Kopito  and  Sitia,  2000).  According  to  this  model,  aggresome building  blocks  are   
produced throughout the cytoplasm by polypeptide coaggregation into single aggresomal 
particles or building blocks. In cells, such particles have  a regular size  (Garcia-Mata et al. 1999; 
Johnston et al. 2000),  supporting the  idea that  a  fixed number of peptides aggregate form 
these building blocks.  After  their  formation,  these  particles  are   transported  to  the   MTOC,  
where   they incorporate into the  final, single aggresome. Electron microscopy has confirmed 
that  building particles are  loosely associated with each other  and  do not coalesce (Garcia-Mata 
et al. 1999; Johnston et  al. 1998).  A similar model have  been described for IBs formation in  
E.  coli: for example,  expression of asparaginase  resulted  in  the  formation,  within  an  
individual  cell,  of a high number of small aggregates which further loosely associate amongst 
themselves to form bigger aggregates (Upadhyay et al. 2012).
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Analysis of purified aggresomes showed that such protein aggregates are not completely pure.  On  the  
contrary, some  impurities  are   co-purified  with   aggregated  recombinant  GLA.  The 
presence  of  such  contaminants  that   co-aggregate  within  eukaryotic  aggresomes  is  not 
unexpected and  has been previously described in the  literature. Chaperone Hsp70  was found 
associated to aggresomes. In this regard, it has been described the  Hsp70  role in promoting 
aggresome  formation  (Zhang   and   Qian,  2011),   based  on  the   Hsp70   interaction  with  the 
cochaperone ubiquitin ligase carboxyl terminal of Hsp70/Hsp90 interacting protein (CHIP). 
Disruption of such Hsp70-CHIP interaction prevents aggresome formation, whereas a dominant- 
negative CHIP mutant  sensitizes the  aggregation of misfolded protein. In another study, Wang 
described the  presence of Hsp70  associated to polyQ aggregates produced in yeast (Wang  et 
al. 2007).  Also, tubulin and  actin are  important components of aggresomes. The  presence of 
cytoskeleton-associated proteins in aggresomes is not surprising: the  large size  of mammalian 
cells, together with the presence of the cytoskeleton, a structure that could restrict the motility of 
particulate material (Gershon et al. 1985),  implies that non-difussional mechanisms are  needed 
to  sequester  aggregates  within  the  cytoplasm  and   transport  them   to  the  MTOC.  For  that 
purpose, formation  of aggresomes must  exploit  the  transport on microtubules  (Garcia-Mata et 
al. 1999;  Johnston et al. 2002;  Kopito, 2000;  Kopito and  Sitia, 2000),  resulting in the  fact that 
cytoskeleton-related  proteins,  like  vimentin,  tubulin,  actin  and   others,  are   usually  found 
intimately associated with aggresomes. It has been shown  that  small aggregates generated at 
the  cell periphery are  transported within the  cytoplasm at  a  rate  of 0.32  µm/min towards the 
aggresome  (Garcia-Mata et   al.  1999).   A  model  for  microtubule-based  delivery  of  protein 
aggregates  to  aggresomes has  been described  (Kopito,  2000;   Kopito  and   Sitia,  2000).   In 
agreement with our results, it has been described the  presence of -tubulin, as an  aggresome- 
related protein in  -synuclein-containing aggresomes (Chiba et  al. 2012)  and  in 
perinuclear aggregate  bodies   formed   by   a   truncated  protein   containing   expanded  
polyQ   stretches 
(Shimohata et al. 2002). All these studies corroborate our findings about  the presence of Hsp70 
 
chaperone, actin and tubulin as aggresomes-related proteins. 
 
 
Finally,  aggresomes  showed  protection of the sequestered form of the enzyme within the 
aggresome fraction towards thermal inactivation in solution, and  in our testing system could be 
reused at least up to 5 rounds of consecutive enzymatic assays (Fig. 5). 
 
 
The proof-of-concept shown  here  of aggresomes as immobilized biofunctional particles could be 
in  the  line  of  the  development  of  a  new  type  of  biomaterial,  similarly  to  the  application  of 
bacterial IBs as protein release nanoparticles in tissue engineering and  substitutive therapies 
(Seras-Franzoso et al. 2013a; Seras-Franzoso et al. 2013b;  Seras-Franzoso et al. 2014) . Since 
some eukaryotic proteins are  not produced in their active form when  expressed in prokaryotic 
systems, mammalian  aggresomes could be  an  alternative  to  package functional proteins in 
mechanically  stable,  protein  releasing  nano-microstructured  materials.  GLA glycosylation  itself 
has been described  as crucial  to the  enzyme activity  (Ioannou  et  al.  1998),  hampering  their
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production in bacterial expression systems. In this context,   it  has been possible to  adapt a 
purification protocol for aggresomes to the  peculiar functional demands of aggresomes (mainly 
its optimal pH for catalytic activity). In summary, since  mammalian cell aggresomes retain the 
enzymatic activity of their protein components, show improved stability versus soluble protein 
versions, and  can  be  purified by function-friendly protocols, we  propose these structures as a 
novel type  of carrier-free, self-assembled immobilized biomaterial, with putative applications in 
biotechnology and  biomedicine. This strategy could be of special interest for those proteins that, 
like GLA, cannot be expressed in prokaryotic systems. The model GLA used in this work formed 
enzymatically  active  aggresomes, representing  a  proof-of-concept  for such   aggregates as a 
new type of carrier-free, self-assembled immobilized biomaterial. However, in addition, - 
galactosidases are also of particular interest regarding biotechnological and biomedical 
applications, and  GLA aggresomes could have  putative applications in both  biotechnological 
(such   as the  removal  of  raffinose  oligosaccharides  from  several  legume-based  foods)  and 
biomedical fields (such  as improved methods to deliver enzymatically active GLA in the  field of 
innovative enzyme replacement therapies in Fabry disease patients).
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Figure captions 
 
 
Fig 1 GLA kinetics production in transiently transfected HEK 293F cells. Samples were  collected 
 
3, 4 and  5 days post-transfection, and  processed as indicated in “Material and  Methods”  section 
in order  to  separate the  soluble, secreted (“Extracel”) fraction from the  insoluble (“Ins”) and 
soluble (“Sol”) intracellular protein forms. Samples from non-transfected 293F  cells taken  at day 
5 (labelled as “Mock cells, 5d”) were  treated with the same protocol and  included as a negative 
control. Legend: MW: molecular weight marker.  C+: positive control (purified, soluble GLA) 
 
 
Fig 2 TEM images of HEK 293F  cells transfected with pOpinE-GLA expression vector.  Images 
correspond to cells before transfection (panels a, b), 3 days (panels c, d) and  5 days (panels e, 
f) after transfection. White arrows point out individual aggresomes. In panels 2d and  2f, closer 
views allow to distinguish the spherical building blocks that compose GLA aggresomes 
 
 
Fig 3 SEM images  of purified  GLA aggresomes. Panel  a: SEM image  of aggresomes purified 
with “acetic acid  disrupting buffer” from cells harvested 5 days post-transfection. In panel b, a 
closer view allows to clearly distinguish the spherical aggresomes building blocks 
 
 
Fig 4 Solubilization of GLA aggresomes. Spontaneous solubilization of GLA aggresomes was 
followed by measuring the remaining enzymatic activity in the aggresome fraction (panel a) and 
the  simultaneous  increase  of enzymatic  activity  in  the  supernatant (panel  b).  Similar  results 
were   obtained  when   following  solubilization  by  estimating  the  GLA protein  amount  in  the 
aggresome fraction (panel c) and  in the supernatant (panel d). Data  shown  represents mean +/- 
SEM of 4 independent samples tested each in duplicate (total n=8) 
 
 
Fig 5 Stability and  reusability of GLA aggresomes. Panel a: Stability of GLA aggresomes (black 
circles)  versus soluble, secreted GLA (white circles),  was followed by measuring the  remaining 
enzymatic  activity  of  both  materials  when   incubated  in  acetic  acid  buffer,  at  37ºC,   for  
the indicated time periods. Panel b: Reusability was evaluated by performing successive 
enzymatic activity  measurements (“rounds”),  and  further  comparison  with  “Round  1”  (activity  
defined  as 
100 %). For both types of experiments, data  shown  represents mean +/- SEM of 2 independent 
samples tested each in triplicate (total n=6) 
